# US 2015/0104849 A1 · Methods of purifying recombinant adamts13 and other proteins and compositions thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104849 A1
- Document ID: US20150104849A1
- Status: Published application
- Kind: A1
- Application number: 14/571,670
- Filed: 2014-12-16
- Published: 2015-04-16
- Earliest claimed: 2009-07-31
- Assignees: Baxter Healthcare S.A.; Baxter International Inc.
- Applicants: Baxter Healthcare S.A.; Baxter International Inc.
- Inventors: Meinhard Hasslacher; Christian Fiedler; Christa Mayer; Artur Mitterer
- Web page: https://patentgrep.com/patent/US20150104849A1

## CPC

- C12N 9/6489: {Metalloendopeptidases (3.4.24)}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12M 47/12: {Purification (C12M47/04 takes precedence)}
- C12N 11/14: Enzymes or microbial cells immobilised on or in an inorganic carrier
- C12Y 304/24087: ADAMTS13 endopeptidase (3.4.24.87)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12Y: ENZYMES

## Abstract

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.

## Claims

### Claim 1

A method for purifying recombinant a disintegrin-like and metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13) protein from a sample comprising ADAMTS13 protein and non-ADAMTS13 impurities, the method comprising chromatographically contacting the sample with hydroxyapatite under conditions that allow said ADAMTS13 protein to appear in an eluate or a supernatant from said hydroxyapatite.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising chromatographically contacting said eluate with a cation exchange/hydrophobic interaction resin that binds said ADAMTS13 protein.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2, further comprising chromatographically contacting said sample with an anion exchange resin and eluting said ADAMTS13 protein from said anion exchange resin before chromatographic contact with said hydroxyapatite.

### Claim 4 (depends on 1, 2)

The method according to claim 1 or 2, further comprising concentrating said ADAMTS13 protein in said sample by ultrafiltration; and stabilizing said ADAMTS13 protein by diafiltration exchange into a buffer comprising calcium ions and zinc ions before chromatographic contact with said hydroxyapatite.

### Claim 5 (depends on 2)

The method according to claim 2, further comprising, following contact with said hydroxyapatite or said cation exchange/hydrophobic interaction resin, the step of preparing said ADAMTS13 protein for cation exchange by reducing buffer conductivity.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said preparing step is performed by ultrafiltration/diafiltration.

### Claim 7 (depends on 5)

The method according to claim 5, wherein said preparing step is performed by dialysis, said dialysis consisting of no more than 2 passes through a single dialysis module.

### Claim 8 (depends on 5)

The method according to claim 5, wherein said preparing step is performed by gel filtration.

### Claim 9 (depends on 1, 2)

The method according to any one of claim 1, 2, or 5, further comprising subjecting said ADAMTS13 protein to at least one virus inactivation step.

### Claim 10

The method according to 9, wherein said virus inactivation step comprises adding a solvent-detergent mixture comprising a non-ionic detergent and an organic solvent to said ADAMTS13 protein.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said ADAMTS13 protein is immobilized.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said ADAMTS13 protein is immobilized on a cation exchange resin.

### Claim 13 (depends on 10)

The method according to claim 10, wherein said solvent-detergent mixture comprises 1% TRITONX-100, 0.3% Tri-N-butyl phosphate, and 0.3% TWEEN 80.

### Claim 14 (depends on 9)

The method according to claim 9, wherein said virus inactivation step comprises filtering said ADAMTS13 protein with a nanofilter to remove viruses and/or viral particles.

### Claim 15 (depends on 9)

The method according to claim 9, wherein said virus inactivation step is performed after said preparing step.

### Claim 16 (depends on 12)

The method according to claim 12, further comprising eluting said ADAMTS13 protein from said resin using gradient elution, said gradient elution using a first buffer having low salt content and a second buffer having higher salt content.

### Claim 17 (depends on 12)

The method according to claim 12, further comprising eluting said ADAMTS13 protein from said resin using step elution.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said step elution comprises eluting said ADAMTS13 protein from said resin with a storage buffer.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said storage buffer has a pH of greater than 7.0 and comprises less than 10 mM calcium ions, a buffering compound, 0.05% non-ionic detergent, and a salt.

### Claim 20 (depends on 18)

The method according to claim 18, wherein there is no subsequent concentration or buffer exchange step.

### Claim 21 (depends on 1, 2)

A composition comprising a recombinant ADAMTS13 protein prepared according to the method of any one of claim 1, 2, or 5.

### Claim 22 (depends on 12)

A composition comprising a recombinant ADAMTS13 protein prepared according to the method of claim 12.

### Claim 23

A method for inactivating virus contaminants in a protein sample, said method comprising:
immobilizing said protein on a support; and
treating said immobilized protein with a solvent-detergent mixture comprising a non-ionic detergent and an organic solvent.

### Claim 24 (depends on 23)

The method according to claim 23, wherein said protein is at least one selected from ADAMTS13, Advate, Factor VIIa, Factor IX, von Willebrand factor, and anti-MIF antibody.

### Claim 25 (depends on 23)

The method according to claim 23, wherein said support is a chromatographic resin.

### Claim 26 (depends on 23)

The method according to claim 23, wherein said solvent-detergent mixture comprises 1% Triton X-100, 0.3% Tri-N-butyl phosphate, and 0.3% Polysorbate 80.

### Claim 27 (depends on 23)

The method according to claim 23, wherein said solvent-detergent mixture treatment continues for 30 minutes to 1 hour.

### Claim 28 (depends on 23)

The method according to claim 23, further comprising eluting said protein from said support with a storage buffer.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said storage buffer has a pH of greater than 7.0 and comprises less than 10 mM calcium ions, a buffering compound, 0.05% non-ionic detergent, and a salt.

### Claim 30 (depends on 28)

The method according to claim 28, wherein there is no subsequent concentration or buffer exchange step.
